| Literature DB >> 30736810 |
Gustavo Tomás Díaz-Gerevini1,2, Alejandro Daín1, María Eugenia Pasqualini1, Cristina B López1,3, Aldo R Eynard1, Gastón Repossi4.
Abstract
BACKGROUND:Entities:
Keywords: Diabetic encephalopathy; Nordihydroguaiaretic acid; Polyunsaturated fatty acids ω3; eSS rats, diabetes mellitus
Mesh:
Substances:
Year: 2019 PMID: 30736810 PMCID: PMC6368734 DOI: 10.1186/s12944-018-0938-7
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Experimental groups and content of IP injections received as treatments
| Rat strain | Group name | Treatment (0.4 ml IP) |
|---|---|---|
| eSS | Control eSS | Diabetic control. Only saline isotonic solution |
| eSS | ω6 | Saline isotonic solution plus 6.25 mg/kg of 90% AA |
| eSS | ω6 + NDGA | Saline isotonic solution plus 6.25 mg/kg of 90% AA oil + 1.19 mg/kg NDGA |
| eSS | ω3 | Saline isotonic solution plus 6.25 mg/kg of commercial fish oil containing 35% eicosapentaenoic acid (EPA) and 40% docosahexaenoic acid (DHA) |
| eSS | ω3 + NDGA | Saline isotonic solution plus 6.25 mg/kg of commercial fish oil + 1.19 mg/kg NDGA |
| Wistar | Wistar | Non- diabetic control. Only saline isotonic solution |
Fig. 1Glycaemic metabolism. OGGT of experimental animals performed at 2, 6 and 12 months. a Fasted glycaemia (mg/dl), b postprandial glycaemia (mg/dl) and c HbA1c levels (%). Data are expressed as mean ± SEM. * Indicate significant difference to Control eSS, p ≤ 0.05
Fig. 2Blood lipids. Levels of plasmatic (a) triglycerides and b total cholesterol of animals at 2, 6 and 12 months. Data are expressed as mean ± SEM. * Indicate significant difference to Control eSS, p ≤ 0.05
Plasma total fatty acid profiles by GC
| Experimental groups | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control eSS | ω6 | ω6 + NDGA | ω3 | ω3 + NDGA | Wistar | |||||||
| Fatty acids | ||||||||||||
| SFA | 23,56# | ±2,28 | 45,89#* | ±3,46 | 38,20#* | ±3,18 | 22,20#* | ±0,34 | 25,00#* | ±2,90 | 27,90* | ±2,53 |
| MUFAs | 27,60# | ±2,60 | 17,46#* | ±1,51 | 24,50#* | ±1,29 | 33,30* | ±0,25 | 45,40# | ±0,76 | 22,50* | ±1,36 |
| PUFAs ω6 | 38,20 | ±3,65 | 30,37#* | ±0,10 | 23,70#* | ±1,09 | 29,00* | ±0,04 | 12,00* | ±0,44 | 38,00* | ±3,18 |
| PUFAs ω3 | 4,00# | ±0,54 | 1,83 | ±0,01 | 6,20 | ±0,33 | 15,10 | ±0,16 | 19,30# | ±0,48 | 16,40* | ±0,36 |
| PUFAs Total | 42,20 | ±2,09 | 32,20# | ±0,05 | 29,10# | ±0,71 | 44,00 | ±0,10 | 31,10# | ±0,46 | 54,30* | ±1,77 |
| Ratio ω6/ω3 | 9,55# | 16,60# | 3,82#* | 1,92* | 0,62* | 2,32* | ||||||
Profiles was determined at 12TH month of age in experimental groups
#Indicate significant difference to Wistar, p ≤ 0.05. *Indicate significant difference to Control eSS, p ≤ 0.05
Fig. 3Behaviour Evaluation by Hole Board Test. a Head deeping, b Time Movement and c Rearing. Data are expressed as mean ± SEM. # Indicate significant difference to Control eSS at 6th month, p ≤ 0.05. * Indicate significant difference compared to Control eSS at 12th month, p ≤ 0.05
Fig. 4Histological sections of hippocampus. a Cell dispersion (black arrow) and thickness (white arrow) of the hippocampal CA1 zone, at 12 months of aging. Nissl 40x. b Histopathological analysis. Data are expressed as mean ± SEM * Indicate significant difference to Control eSS at the end of 12 months, p ≤ 0.05
Fig. 5Apoptosis. Hippocampal apoptosis in animals at the end of 12 months (a) by flow cytometry, b by TUNEL. Data are expressed as mean ± SEM. * Indicate significant difference to Control eSS, p ≤ 0.05
Fig. 6Immunohistochemical staining by synaptophysin. Analysis of levels of SYN protein in hippocampus slides. Data are expressed as mean ± SEM. *Indicate significant difference to Control eSS, p ≤ 0.05
Fig. 7Levels of inflammatory markers. a Plasmatic high-sensitive CRP concentration. Levels of IL-6 measured in b plasma and c hippocampus. Markers were measured in animals at 12 month. Data are expressed as mean ± SEM. * Indicate significant difference to Control eSS, p ≤ 0.05
Fig. 8Stress oxidative markers. Markers were determined in animals at 12 month. a GGTP enzyme activity measured in plasma and brain tissue. b Plasmatic hydroperoxides and lipoperoxides assays. Data are expressed as mean ± SEM. * Indicate significant difference to Control eSS, p ≤ 0.05